LY171883 |
Catalog No.GC13087 |
leukotriene D4 receptor antagonist, orally active
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 88107-10-2
Sample solution is provided at 25 µL, 10mM.
LY171883 is a leukotriene D4 receptor antagonist.
Leukotriene D4 is one of the leukotrienes, whose major function is to induce the smooth muscle contraction, leading to vasoconstriction and bronchoconstriction. Leukotriene D4 can also increase vascular permeability.
In vitro: In GH(3) cells, LY-171883 was able to reversibly increase the amplitude of Ca(2+)-activated K(+) current concentration-dependently with an EC(50) value of 15 μM. Moreover, the treatment of LY-171883 to cytosolic face did not affect single channel conductance of large-conductance Ca(2+)-activated K(+) channels in excised inside-out patches recorded from GH(3) cells, however, LY-171883 did increase the channel activity. In addition, the LY-171883-stimulated activity of BK(Ca) channels was dependent on membrane potential [1].
In vivo: The effect of LY-171883 on the respiratory and cardiovascular changes in endotoxemia was studied in unanesthetized sheep. In group one, LY-171883 at 4 mg/kg was i.v. injected. In group two, Escherichia coli endotoxin (1 μg/kg) was infused, and in group three, LY-171883 at 4 mg/kg was administered before and after the same dose of endotoxin. Results showed that infusion of LY-171883 in group one did not alter baseline ventilatory and cardiovascular measurements. In group two, a two-phase pulmonary response was found. An early pulmonary hypertension phase with a fall in cardiac index was observed in group three [2].
Clinical trial: Up to now, no clinical data have been released.
References:
[1] PC Li et al. Enhanced Activity of Ca2+-Activated K+ Channels by 1-[2-Hydroxy-3-Propyl-4-[(1h-Tetrazol-5-Yl)butoxyl]phenyl] Ethanone (LY-171883) in Neuroendocrine and Neuroblastoma Cell Lines. J Cell Physiol 192 (2), 188-199. 8 2002.
[2] Gross D, Ben Dahan J, Landau EH, Krausz MM. Effect of leukotriene inhibitor LY-171883 on the pulmonary response to Escherichia coli endotoxemia. Crit Care Med. 1990 Feb;18(2):190-7.
Cas No. | 88107-10-2 | SDF | |
Chemical Name | 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]-ethanone | ||
Canonical SMILES | CCCc1c(OCCCCc2nnn[nH]2)ccc(C(=O)C)c1O | ||
Formula | C16H22N4O3 | M.Wt | 318.4 |
Solubility | ≤25mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | Storage | Room temperature |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.1407 mL | 15.7035 mL | 31.407 mL |
5 mM | 0.6281 mL | 3.1407 mL | 6.2814 mL |
10 mM | 0.3141 mL | 1.5704 mL | 3.1407 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *